Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X

Do More Single Cell with Less

Increase your lab’s sample and project accessibility with the latest Tapestri Platform update.
Let’s talk about your research

Level Up Your Heme-onc Research

There’s a new update to the Tapestri Platform, the only single-cell DNA and multi-omics solution that analyzes genotype and phenotype simultaneously from single cells.

With the latest additions and improvements to Tapestri’s capabilities, researchers of hematologic oncology can now access single-cell insights from as few as 20,000 cells, while conserving precious samples. Get up and running quickly with single-cell experiments with our expanded menu for hematologic malignancies. Now you can do more single cell in less time with lower sample input, enabling new avenues for your research that were previously impossible.

Play Video
INSIGHTS FROM 20K CELL INPUT

Low Input, Big Insights

With our new input requirements down to as few as 20,000 cells, perform single-cell analysis on projects where it wasn’t previously possible, all the while conserving precious samples. Get insights from low input samples without sacrificing performance and the ability to detect rare cells.

Consistent variant signatures and sensitivity observed in low (20k, left) and high (100k, right) inputs of three cell lines. The cell line GM12878 (spiked-in at 5% concentration) is detected consistently, demonstrating that the ability to detect cell populations is unaffected by cell input amounts.
Consistent scDNA-seq performance observed across a range of cell inputs from 20k to 100k cells, as demonstrated by the consistent capture rate of >5% (left) and high panel uniformity of >90% (right) across the range.
READY-TO-USE CONTENT

Expanded Menu for Heme Malignancies

Get up and running quickly and conveniently thanks to pre-designed panels for heme malignancies. The new Tapestri Single-cell DNA Published Panels are sourced from leading researchers covering various indications. These have been featured in peer-reviewed publications, verifying performance.

For simultaneous single-cell DNA and protein analysis, configure your own antibody cocktail from a growing catalog of pre-optimized antibody oligonucleotide conjugates (AOC). Or, start with the pre-designed 45-protein TotalSeq™-D Heme Oncology Cocktail, and then spike in additional AOCs to fit your research needs. TotalSeq™ oligo-conjugated antibodies from BioLegend integrate seamlessly into the Tapestri single-cell DNA sequencing workflow to amplify the power of single-cell analysis.

Tapestri Single-cell DNA Published Panels for Hematologic Malignancies
Acute Lymphoblastic Leukemia Published Panel
Designed by the Jan Cools Lab at Vlaams Instituut voor Biotechnologie
Publication: Albertí-Servera, L. et al. Blood (2021)

Targeting 112 genes with 305 amplicons
Learn more
Myeloproliferative Neoplasms
Published Panel
Designed by the Piers Blombery Lab at Peter MacCallum Cancer Center
Publication: Thompson, E.R. et al. Haematologica (2020)

Targeting 18 genes with 70 amplicons
Learn more
Myeloid Clonal Evolution Published Panel
Designed by the Ross Levine Lab at Memorial Sloan Kettering Cancer Center
Publication: Miles, L. A. et al. Nature (2020)

Targeting 32 genes with 109 amplicons
Learn more
Protein Panels for Hematologic Malignancies
BioLegend TotalSeq-D Heme Oncology Cocktail
Target 42 heme cell surface lineage marker antibodies and 3 negative isotype controls
Learn more
BioLegend TotalSeq-D Antibody Oligonucleotide Conjugates
Configure an antibody cocktail from a catalog of pre-optimized antibody oligonucleotide conjugates
Browse
RECENT PUBLICATIONS

Novel Multi-omics Applications

Profiling hematologic malignancies using single-cell analysis lends insight into how we can better detect and surveil disease, segment patients into clinical trials, and combat resistance to therapies. Investigators have been using the Tapestri Platform to make strides in hematologic oncology research, with breakthrough applications including therapy resistance, clonal hematopoiesis of indeterminate potential (CHIP), and minimal residual disease (MRD). For example, single-cell DNA + protein multi-omics can be leveraged to distinguish MRD from CHIP clones.

Distinguishing malignant AML from CHIP using single-cell multi-omics
Dillon, L.W. et al. Blood Cancer Discovery (2021)
Detecting MRD for AML with single-cell DNA sequencing
Ediriwickrema, A. et al. Blood Advances (2020)
Revealing significance of dysplastic hematopoiesis in multiple myeloma
Maia, C. et al. Blood (2020)
Elucidating AML Clonal Evolution with single-cell multi-omics
Morita, K. et al. Nature Comm (2020)

Get Started

Contact us to begin your evaluation:

REQUEST QUOTE